88 results about "Soft tissue infection" patented technology

Percutaneous skin access devices include a plurality of locked connecting units mounted to the exterior surface of an implantable medical object which, in position, is configured to penetrate the skin of a subject. The locked connecting units may be mounted directly onto the desired surface of the exterior of the device or may be held on a substrate sheet, which is mounted to the exterior surface of the device. In position, the locked connecting units engage with soft tissue which can include the skin to form a bio-junction layer which includes mechanical and bio-sealing connection between the device body and the soft tissue. The configuration at the bio-junction layer secures the medical object in location in the subject even for long-term indwelling applications in a manner, which inhibits soft tissue infection.The locked connecting units may be rigid or semi-rigid for longer-term indwelling applications, and semi-rigid and / or resilient for shorter term indwelling applications. The locked connecting units may take on the form of rings, hooks, or loops having aperture or gap width / length sizes of from about 0.2–4 mm. The rings, loops, or hooks may connect with any soft tissue including skin as well subcutaneous tissue. The rings, hooks, or loops may be released from the skin / tissue without requiring surgical cutting procedures.The locked connecting units may be configured as a semi-rigid mesh collar arranged about the primary body providing access to the subject such that it resides in the subject and engages with the skin (epidermal / dermal layer). The mesh collar can be described as a particular type of ring or loop structure as the mesh defines the gap provided in individual loop configurations. The mesh collar may be used alone, or in combination with the loops, rings, or hooks. A skin stop collar having increased rigidity may be disposed under the mesh collar.

A bioresorbable material is incorporated with bioactive agents to form an implant used for treatment against hard tissue or soft tissue defects and diseases. Antibiotics or anti-cancer agents are incorporated to treat hard or soft tissue infections or cancers. Sustained release of the bioactive agents or drug molecules may be achieved after implantation at the targeted sites. The dosage of the active agents or molecules, the microstructure, morphology, and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy. Various microstructure and the morphologies of the implants are injectable like putty or shaped with multilayers.

A crystallized cefathiamidine is prepared from the cefathiamidine solution through controlling pH to 3.5-6.5, adding proper solvent until the solution becomes cloudy, controlling saturation procedureand crystal growth speed while adding said solvent, separating and drying. Its advantage is uniform granularity. It can be used to prepare the medicines for treating the infection of staphylococcus aureus, pneumoccus, enterococcus, streptococcus, etc.

The invention relates to a cefathiamidine hydrate, a preparation method thereof and application thereof. The crystalline hydrate has high storage stability, and is applicable in preparing medicaments for treating or preventing gram positive or negative bacteria sensitive bacteria, infections of human or animal respiratory system, liver and biliary system, five sense organs and urogenital system, bone and joint infection and soft skin tissue infection caused by the gram positive or negative bacteria sensitive bacteria, and diseases such as endocarditis, ichorrhemia, meningitis and the like.

The invention relates to a cefpiramide sodium hydrate and a preparation method and application thereof. The cefpiramide sodium hydrate has high storage stability, and is applicable to the preparation of medicines for treating or preventing diseases of the human being or animals caused by gram-positive or gram-negative sensitive bacteria, such as respiratory system diseases, hepatobiliary system diseases, five-sense organ diseases, urinary tract infection, celiac infection, pelvic infection, ichorrhemia, skin tissue infection, bone and joint infections, endocarditis and cephalomeningitis.

The present invention relates to medicine technology and is improved mezlocillin sodium injection. The injection has one medicine weight ratio of mezlocillin sodium / Sulbactam sodium 1-16 to 1. It hasstrong antibacterial activity, wide antibacterial spectrum and thus high curative effect, and may be used in treating serious urinary tract infection, respiratory tract infection, intestinal tract, otorbinolaryngological infection, abdominal cavity infection, etc. caused by zymogenic staphylococcus, pneumococcus, enterococcus, purulent streptococcus, Hemophilus infuenzae, etc.

The invention discloses a cefuroxime sodium compound entity which is relatively poor in hygroscopicity, relatively good in storage stability and applicable to preparation of drugs for treating or preventing respiratory system infection, five-organ infection, urinary system infection, pelvic cavity infection, septicemia, skin soft-tissue infection, bone and joint infection, gonorrhea and meningitis of human or animals, caused by sensitive gram positive or negative bacteria.

The invention provides a Peptocin antibacterial peptide separated from heterometrus spinifer and obtained through a chemical synthesis method. The antibacterial peptide has a remarkable antibacterial effect on clinically-separated multi-drug resistant acinetobacter baumannii, and can be used for efficiently inhibiting the growth of the drug resistant acinetobacter baumannii; and meanwhile, human red blood cell toxicity tests also show that the antibacterial peptide is small in toxicity and can be applied to the preparation of drugs for treating or preventing diseases caused by the drug resistant acinetobacter baumannii and particularly to the preparation of drugs for treating serious infectious diseases such as ventilator-associated pneumonia, septicemia, meningitis, otitis media, skin soft-tissue infection, urinary system infection, central nervous system infection and the like caused by the drug resistant acinetobacter baumannii. The antibacterial peptide provided by the invention is remarkable in inhibiting effect on gram bacteria, unique in antibacterial mechanism and low in toxicity, and can also be applied to the preparation of drugs for treating or preventing diseases caused by micrococcus luteus, salmonella and other gram bacteria.

The invention provides a cefoperazone sodium compound entity and a composition thereof. The cefoperazone sodium compound entity is low in hygroscopicity and good in storage stability, is suitable in an application of preparing drugs for treating or preventing respiratory system infection, infection in the five sense organs, urinary system infection, pelvic cavity infection, septicemia, skin soft tissue infection, infection in bones and joints, gonorrhea and meningitis of human or animal due to bacteria being sensitive to gram-positive bacteria or gram-negative bacteria.

In order to overcome symptoms of wound infection, short healing time, relapse and infection, easy incrustation to form scar proliferation and nonunion of wound for long treatment in conventional treatment of traumas as well as allergy to antigen of diabetics and nonunion of wounds of fragile patients, the invention provides a formula of paste for removing slough and promoting growth of tissue regeneration. The formula comprises the following traditional Chinese medicines in parts by weight: 18-22 parts of frankincense, 18-22 parts of myrrh, 13-17 parts of elephant hide, 13-17 parts of lithospermum, 18-22 parts of angelica sinensis, 23-28 parts of astragalus membranaceus, 13-18 parts of muskone, 22-27 parts of propolis, 13-17 parts of salviae miltiorrhizae and 13-17 parts of golden cypress. The forming state of the medicine is a paste or powder. The paste provided by the invention can regenerate severed fingers and heal malignant traumas and infection of soft tissues for long treatment while heals non-pathogenic traumas and pathogenic traumas as well as sport injuries. The patients do not use antibiotics which cause dysfunction of the body. The using method is simple and convenient, and no pains are generated during secondary wet treatment, so that pains of the patients are reduced, and the treatment cost and time are shortened.

The invention relates to a cefonicid sodium hydrate and a preparation method and application thereof. The cefonicid sodium hydrate has better storage stability and is applicable to preparation of the medicaments for treating or preventing such diseases caused by gram positive or negative sensitive bacteria as respiratory system infection, hepatobiliary system infection, five sense infection, urinary tract infection, abdominal infection, pelvic infection, sepsis, skin soft tissue infection, bone and joint infections, annexitis, intrauterine infection, parametritis, meningitis, gonorrhea and the like of human or animals.

A freeze-dried powder injection of clindamycin hydrochloride for treating various infectious diseases, tonsillitis, tympanitis, acute bronchitis, pneumonia, etc is prepared from clindamycin hydrochloride through ultrafiltration, mixing with filtered mannitol in dark condition and N2 atmosphere, pouring in containers, freeze drying, and sealing.

The invention belongs to the novel technical field of medicament, specifically relates to cefdinir dry suspension applied to the treatment of inflection caused by staphylococcus, streptocoaus, propionibacterium, gonococcus, colibacillus, Klebsiella pneumoniae, proteus mirabilis, hemophilus influenzae, and Providence bacteria such as pharyngolaryngitis, tonsillitis , bronchitis, pneumonia, pyelonephritis, cystitis and gynaecologic, surgical, dermal, and soft tissue infection.

The invention provides an antibacterial composition of sulbenicillin sodium for injection, which comprises sulbenicillin sodium and sulbactam sodium by the weight ratio of 1-32:1. The antibacterial compound preparation has substantial synergy actions, and can effectively inhibit the reactivity of beta-lactamase.

The invention relates to a cefotetan disodium hydrate and a preparation method and application thereof. The cefotetan disodium hydrate has high storage stability, and is applicable to the preparation of medicines for treating or preventing diseases of the human being or animals caused by gram-positive or gram-negative sensitive bacteria, such as respiratory system diseases, hepatobiliary system diseases, five-sense organ diseases, urinary tract infection, celiac infection, pelvic infection, ichorrhemia, skin tissue infection, bone and joint infections, cephalomeningitis and endocarditis.

The invention relates to a cefodizime sodium hydrate, a preparation method thereof and application thereof. The cefodizime sodium hydrate has high storage stability, and is suitable to be used in the preparation of medicaments for treating and preventing diseases, caused by Gram-positive or negative bacterial sensitive bacteria, such as diseases in respiratory systems, liver and gall systems and five sense organs of human beings and animals, urinary tract infection, enterocoelia infection, pelvic cavity infection, ichorrhemia, skin and soft tissue infection, bone and joint infection, annexitis, intrauterine infection, parametric connective tissue inflammation, cephalomeningitis, gonorrhoea and the like.

The present invention relates to a crystal form of lomefloxacin aspartate and a preparation method thereof. The present invention also relates to a pharmaceutical composition containing the above-mentioned crystal form of lomefloxacin aspartate and the crystal form is used to manufacture a treatment for Gram Human or animal respiratory tract infection, genitourinary system infection, gastrointestinal bacterial infection, abdominal cavity, biliary tract, typhoid and other infections, bone and joint infection, skin and soft tissue infection, sepsis and other systemic infection caused by positive or negative bacterial sensitive bacteria, Other infections, such as sinusitis, otitis media, blepharitis and other drugs.

The invention relates to cefathiamidine monocrystal, a preparation method, use and a composition thereof. The cefathiamidine monocrystal disclosed by the invention is prepared by comprising the following steps of: adding three solvents, namely ethanol, water and acetone, into a clean conical flask in any sequence according to any proportion, wherein the volume ratio of ethanol, water to acetone is (4-10):1:(0.05-3.67), during, before or after adding various solvents, adding cefathiamidine, dissolving at room temperature, and preparing cefathiamidine solution with the concentration of 0.05-0.5 g / ml; sealing by using a plastic film, and pricking a plurality of small holes on the plastic film; storing at 0-15 DEG C; and beginning to generate tiny crystals after about 48 h, and then obtaining cefathiamidine monocrystal after above 96 h. The preparation method disclosed by the invention is simple and convenient for operation and simple in equipment; the prepared monocrystal is good in stability; the cefathiamidine monocrystal composition disclosed by the invention is a composition composed of monocrystal and pharmaceutically acceptable carriers, preferably injection; the cefathiamidine monocrystal disclosed by the invention can be used for preparing medicines for treating respiratory tract infection, biliary tract infection, urinary tract infection, wound and surgical infection, skin and soft tissue infection, gynaecological infection, ear-nose-throat infection, endocarditis, blood poisoning, pneumonia and meningitis.

The invention relates to an anti-infection oral medicinal preparation and discloses a cefprozil medicinal composition. The cefprozil medicinal composition comprises cefprozil serving as an active ingredient, at least one filling agent, at least one disintegrating agent, at least one lubricating agent, 1 to 10 weight percent of pregelatinized starch and 0.5 to 2 weight percent of hydroxypropyl methylcellulose. The invention also relates to a preparation method for the preparation and application of the preparation to treatment for upper respiratory tract infection, lower respiratory tract infection and skin and skin soft tissue infection.

The invention relates to a sodium fusidate powder-injection pharmaceutical composition for injection and a preparation method. Specifically, the invention belongs to the technical field of medicines, relates to a medicine which can be used for treating various infections such as osteomyelitis, sepsis, endocarditis, repeatedly infected cystic fibrosis, pneumonia, skin and soft tissue infections, surgical and traumatic infections and the like caused by various sensitive bacteria, especially staphylococcus, and particularly relates to a pharmaceutical composition such as a freeze-dried powder injection prepared by taking sodium fusidate as an active component. The invention also relates to a preparation method of the pharmaceutical composition. In an implementation scheme, the invention relates to a sodium fusidate powder-injection pharmaceutical composition for injection, which comprises sodium fusidate, a neutral amino acid and an alkaline amino acid. The pharmaceutical composition has excellent pharmaceutical properties.

A composite medicine for treating various bacterial and viral infections is prepared from the Yanhuning (dehydroandrographolide0potassium sodium succinate), cephalo- type antibiotics, and medicinal auxiliaries. Its preparing process is also disclosed.

The invention discloses moxifloxacin hydrochloride liniment and a preparation method thereof. The moxifloxacin hydrochloride liniment is used for treating respiratory tract, skin and soft tissue infection caused by sensitive bacteria. Chitosan is added to the moxifloxacin hydrochloride liniment, is deacetylation products of shellfishes, and is good in biocompatibility, film-forming property and stickiness, certain antibiosis, antiphlogosis and hemostasis functions are achieved, the chitosan is novel excellent medical pharmaceutic adjuvant, the liniment prepared from the chitosan and moxifloxacin hydrochloride can achieve partial topical application, the first pass effect of the liver and the gastrointestinal tract effect are avoided, bioavailability is improved, and the curative effect is enhanced. Oleum morrhuae is rich in vitamin A and vitamin E, and growth of granulation tissue can be promoted. Glycerinum can assist in dissolving of moxifloxacin hydrochloride, and can also increase medicine transdermal absorption. The liniment is good in adhesive force, good in spreading performance, fast in film forming and not prone to falling off, certain tearing strength is achieved, and cleaning is easy. The preparation process is simple, the content measuring result is accurate, quality is stable, use is safe and convenient, and the liniment is suitable for hospital preparations.

The invention belongs to the novel technical field of medicaments, and relates to a novel dosage form of amoxicillin used for treating: 1, upper respiratory tract infections, such as tympanitis, nasosinusitis, pharyngitis and tonsillitis resulted from streptococcus hemolyticus, streptococcus pneumoniae, staphylococcus or haemophilus influenzae; 2, genitourinary tract infections resulted from escherichia coli,proteus mirabilis or enterococcus faecalis; 3, skin and soft tissue infection resulted from streptococcus hemolyticus, staphylococcus bacteria or escherichia coli; 4, lower respiratory tract infections, such as acute bronchitis and pneumonia, resulted from streptococcus hemolyticus, streptococcus pneumoniae, staphylococcus bacteria or haemophilus influenzae; 5, acute simple gonorrhea; and 6, typhoid, typhoid bacteria-carrier, leptospirosis and the like. The novel dosage form is characterized in that the stomach floating tablet is hydrated into gel on the surface to expand the volume thereof after contacting with the gastric juice at the body temperature because of a plurality of hydrophilic macromolecular materials contained. Meanwhile, the weight of the tablet is less than the buoyant force of the gastric juice to float the tablet on the gastric juice and prolong the retention time in the stomach.

The invention relates to a cefonicid sodium hydrate and a preparation method and application thereof. The cefonicid sodium hydrate has better storage stability and is applicable to preparation of the medicaments for treating or preventing such diseases caused by gram positive or negative sensitive bacteria as respiratory system infection, hepatobiliary system infection, five sense infection, urinary tract infection, abdominal infection, pelvic infection, sepsis, skin soft tissue infection, bone and joint infections, annexitis, intrauterine infection, parametritis, meningitis, gonorrhea and the like of human or animals.

The invention relates to a lomefloxacin aspartate hydrate and the preparation, as well as the usage. The lomefloxacin aspartate hydrate of the invention (the molecular formula is C17H19F2N3O3.C4H7NO4.nH2O, n is equal to 0.5 to 2.5), the lomefloxacin aspartate hydrate of the invention is the fluoroquinolone antibacterial agent used for human or animal respiratory infection, genitourinary infection, gastrointestinal tract bacterial infection, abdominal infection, bile duct infection, typhoid and other infections, bone and joint infection, skin soft tissue infection, sepsis and other systemic infection, other infections, such as paranasal sinusitis, otitis media, blepharitis and so on which are caused by Gram positive or negative bacteria and sensitive bacteria, the invention has the advantages of stable existence, easy storage and transportation and convenient preparation of the pharmaceutical preparations.